New hope for kids with hodgkin lymphoma: modified chemo regimen tested in china

NCT ID NCT04726501

Ongoing Disease control Sponsor: Children's Cancer Group, China Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a modified chemotherapy regimen (based on a U.S. protocol) in 200 Chinese children and teens with newly diagnosed Hodgkin lymphoma. Depending on risk level, patients receive 4 to 6 cycles of chemotherapy, with or without low-dose radiation. The goal is to see if this approach can improve event-free survival and overall survival in this population.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Combination chemotherapy (AVE-PC or ABVE-PC) with or without involved-field radiotherapy
What this could lead to: If successful, this could confirm that a modified COG protocol works well for Chinese children with Hodgkin lymphoma, potentially improving event-free and overall survival rates.
What could go wrong: This is a single-country, non-randomized study with only 200 participants, so results may not apply broadly. Chemotherapy and radiotherapy carry risks like infection, organ damage, and secondary cancers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hodgkins lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HODGKIN LYMPHOMA

Contacts and locations

Locations

Nanjing Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

Nanjing, China
Shanghai Children's Medical Center

Shanghai, 200127, China
West China Second University Hospital, Sichuan University, Chengdu, China

Chengdu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.